Geneva-based Antion Biosciences develops next-gen, safety-enhanced anti-CD19 CAR T-cells for B-cell driven autoimmune diseases.

Antion Biosciences, a Geneva-based cell and gene therapy company, announces development of next-gen, safety-enhanced, off-the-shelf anti-CD19 CAR T-cells for B-cell driven autoimmune diseases. This follows recent findings indicating CAR T-cell therapy's effectiveness in severe autoimmune cases, with potential to cure patients. Autoimmunity, affecting 10% of the global population, has a yearly care burden exceeding $120bn.

May 22, 2024
4 Articles

Further Reading